Estimation of delivered dose to lung tumours considering setup uncertainties and breathing motion in a cohort of patients treated with stereotactic body radiation therapy

2021 ◽  
Vol 88 ◽  
pp. 53-64
Author(s):  
Kristin Karlsson ◽  
Ingmar Lax ◽  
Elias Lindbäck ◽  
Vitali Grozman ◽  
Karin Lindberg ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Tumours ◽  
Stereotactic Body Radiation ◽  
Breathing Motion ◽  
Delivered Dose

Accumulated Delivered Dose Response of Stereotactic Body Radiation Therapy for Liver Metastases

2015 ◽  
Vol 93 (3) ◽  
pp. 639-648 ◽  
Author(s):  
Anand Swaminath ◽  
Christine Massey ◽  
James D. Brierley ◽  
Rob Dinniwell ◽  
Rebecca Wong ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Liver Metastases ◽  
Dose Response ◽  
Stereotactic Body Radiation Therapy ◽  
Stereotactic Body Radiation ◽  
Delivered Dose

Breathing-motion-compensated robotic guided stereotactic body radiation therapy

2017 ◽  
Vol 194 (2) ◽  
pp. 143-155 ◽  
Author(s):  
Susanne Stera ◽  
Panagiotis Balermpas ◽  
Mark K. H. Chan ◽  
Stefan Huttenlocher ◽  
Stefan Wurster ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Stereotactic Body Radiation ◽  
Breathing Motion

scholarly journals Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience

2017 ◽  
Vol 16 (2) ◽  
pp. 148-154 ◽  
Author(s):  
Sung Jun Ma ◽  
Yusef A. Syed ◽  
Charlotte I. Rivers ◽  
Jorge A. Gomez Suescun ◽  
Anurag K. Singh
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Early Stage ◽  
Survival Rates ◽  
Study Data ◽  
Single Institution ◽  
Lung Tumours ◽  
Stereotactic Body Radiation ◽  
Significant Difference

AbstractBackgroundStereotactic body radiation therapy (SBRT) is a treatment option for patients with early-stage non-small cell lung cancer who are medically inoperable or decline surgery. Here we compare the outcome of patients with centrally located lung tumours who underwent either single fraction (SF)- or five-fraction (FF-) SBRT at a single institution over 5 years.MethodsBetween January 2009 and October 2014, patients with centrally located lung tumours who underwent SBRT were included in this study. Data were retrospectively collected using an institutional review board-approved database. For analysis, the Kaplan–Meier method and competing risks method were used.ResultsIn total, 11 patients received 26–30 Gy in 1 fraction, whereas 31 patients received 50–60 Gy (median 55 Gy) in 5 fractions. After a median follow-up of 12 months for SF-SBRT and 17 months for FF-SBRT groups (p=0·64), 1-year overall survival rates were 82 and 87%, respectively. SF- and FF-SBRT groups showed no significant difference in grade 3+ toxicity (p=0·28). The only grade 4 toxicity (n=1) was reported in the SF-SBRT group. All toxicities occurred >12 months after the SBRT.ConclusionsSF- and FF-SBRT have comparable overall survival. SF-SBRT may have some utility for patients unable to have multi-fraction SBRT.

Sign in / Sign up

Export Citation Format

Share Document